Adverum Biotechnologies Inc. (NASDAQ:ADVM) price on Thursday, June 23, rose 0.41% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $3.67.
A look at the stock’s price movement, the level at last check in today’s session was $3.66, moving within a range at $3.565 and $3.68. Turning to its 52-week performance, $25.67 and $3.34 were the 52-week high and 52-week low respectively. Overall, ADVM moved 7.02% over the past month.
Adverum Biotechnologies Inc.’s market cap currently stands at around $364.32 million. Analysts project the company’s earnings per share (EPS) to be -$0.38, which has seen fiscal year 2021 EPS growth forecast to increase to -$1.52 and about -$1.63 for fiscal year 2022. Per the data, EPS growth is expected to be -10.10% for 2021 and -7.20% for the next financial year.
The average forecast suggests down to a -33.30% growth in sales growth compared to quarterly growth in the same period last fiscal year.
Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was no upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that ADVM is a 50% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
10 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 7 analyst(s) rate the stock as a Hold, 3 recommend ADVM as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Overweight which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
ADVM’s current price about 2.65% and -24.72% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 38.59, while 7-day volatility ratio is 4.30% and 4.19% in the 30-day chart. Further, Adverum Biotechnologies Inc. (ADVM) has a beta value of 1.18, and an average true range (ATR) of 0.15. Analysts have given the company’s stock an average 52-week price target of $7.88, forecast between a low of $4.00 and high of $23.00. Looking at the price targets, the low is -8.99% off recent price level in today’s trading while to achieve the yearly target high, it has to move -526.7%. Nonetheless, investors will most likely welcome a -36.24% jump to $5.00 which is the analysts’ median price.
In the market, a comparison of Adverum Biotechnologies Inc. (ADVM) and its peers suggest the former has performed considerably stronger. Data shows ADVM’s intraday price has changed 0.41% today and -85.73% over the past year. Comparatively, Acceleron Pharma Inc. (XLRN) has moved 1.14% so far today and only 12.57% in the past 12 months. Looking at another peer, we see that Agilent Technologies Inc. (A) price has dipped -0.34% on the day. However, the stock is 64.92% off its price today a year ago. Elsewhere, the overall performance for the S&P 500 and Dow Jones Industrial shows that the indexes are up 0.58% and 0.66% respectively on the day as seen in early trades.
If we refocus on Adverum Biotechnologies Inc. (NASDAQ:ADVM), historical trading data shows that trading volumes averaged 2.45 million over the past 10 days and 2.83 million over the past 3 months. The company’s latest data on shares outstanding shows there are 97.75 million shares.
The 0.30% of Adverum Biotechnologies Inc.’s shares are in the hands of company insiders while institutional holders own 98.80% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 9.57 million on May 27, 2021, giving us a short ratio of 1.81. The data shows that as of May 27, 2021 short interest in Adverum Biotechnologies Inc. (ADVM) stood at 9.77% of shares outstanding, with shares short falling to 12.39 million registered in Apr 29, 2021. Current price change has pushed the stock -66.24% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the ADVM stock continues to rise going into the next quarter.